These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Parallel Synthesis of Hexahydrodiimidazodiazepines Heterocyclic Peptidomimetics and Their in Vitro and in Vivo Activities at μ (MOR), δ (DOR), and κ (KOR) Opioid Receptors. Eans SO, Ganno ML, Mizrachi E, Houghten RA, Dooley CT, McLaughlin JP, Nefzi A. J Med Chem; 2015 Jun 25; 58(12):4905-17. PubMed ID: 25996309 [Abstract] [Full Text] [Related]
25. Opioid agonist efficacy predicts the magnitude of tolerance and the regulation of mu-opioid receptors and dynamin-2. Pawar M, Kumar P, Sunkaraneni S, Sirohi S, Walker EA, Yoburn BC. Eur J Pharmacol; 2007 Jun 01; 563(1-3):92-101. PubMed ID: 17349996 [Abstract] [Full Text] [Related]
26. Identification and Pharmacological Characterization of a Low-Liability Antinociceptive Bifunctional MOR/DOR Cyclic Peptide. Li Y, Eans SO, Ganno-Sherwood M, Eliasof A, Houghten RA, McLaughlin JP. Molecules; 2023 Nov 11; 28(22):. PubMed ID: 38005269 [Abstract] [Full Text] [Related]
30. Spinal interaction between the highly selective μ agonist DAMGO and several δ opioid receptor ligands in naive and morphine-tolerant mice. Szentirmay AK, Király KP, Lenkey N, Lackó E, Al-Khrasani M, Friedmann T, Timár J, Gyarmati S, Tóth G, Fürst S, Riba P. Brain Res Bull; 2013 Jan 11; 90():66-71. PubMed ID: 22995282 [Abstract] [Full Text] [Related]
31. Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone]. Ananthan S, Khare NK, Saini SK, Seitz LE, Bartlett JL, Davis P, Dersch CM, Porreca F, Rothman RB, Bilsky EJ. J Med Chem; 2004 Mar 11; 47(6):1400-12. PubMed ID: 14998329 [Abstract] [Full Text] [Related]
32. Differential development of antinociceptive tolerance to morphine and fentanyl is not linked to efficacy in the ventrolateral periaqueductal gray of the rat. Bobeck EN, Haseman RA, Hong D, Ingram SL, Morgan MM. J Pain; 2012 Aug 11; 13(8):799-807. PubMed ID: 22766006 [Abstract] [Full Text] [Related]
33. Hydromorphone efficacy and treatment protocol impact on tolerance and mu-opioid receptor regulation. Kumar P, Sunkaraneni S, Sirohi S, Dighe SV, Walker EA, Yoburn BC. Eur J Pharmacol; 2008 Nov 12; 597(1-3):39-45. PubMed ID: 18789923 [Abstract] [Full Text] [Related]
38. Functional effects of systemically administered agonists and antagonists of mu, delta, and kappa opioid receptor subtypes on body temperature in mice. Baker AK, Meert TF. J Pharmacol Exp Ther; 2002 Sep 12; 302(3):1253-64. PubMed ID: 12183687 [Abstract] [Full Text] [Related]
39. Binding affinity to and dependence on some opioids in Sf9 insect cells expressing human mu-opioid receptor. Liu ZH, He Y, Jin WQ, Chen XJ, Zhang HP, Shen QX, Chi ZQ. Acta Pharmacol Sin; 2003 Sep 12; 24(9):859-63. PubMed ID: 12956932 [Abstract] [Full Text] [Related]
40. Opioid interactions in rhesus monkeys: effects of delta + mu and delta + kappa agonists on schedule-controlled responding and thermal nociception. Stevenson GW, Folk JE, Linsenmayer DC, Rice KC, Negus SS. J Pharmacol Exp Ther; 2003 Dec 12; 307(3):1054-64. PubMed ID: 14557380 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]